ÌÇÐÄvlog´«Ã½

Liposome Drug Delivery Market Analysis

The liposome drug delivery market is expected to register a CAGR of 8.5% during the forecast period of the study.

COVID-19 impacted the liposome drug delivery market as various R&D activities involving liposome drug delivery were postponed around the world by the respective government of the countries. However, the importance of liposomes in drug delivery was realized soon and intensive research started on the liposome drug delivery system for the treatment of COVID-19 which propelled the market growth in the later phase of the pandemic. For instance, according to the research study published in the Asian Journal of Pharmaceutical Sciences in November 2021, the researchers developed lyophilized remdesivir liposomes (Rdv-lips), which could be reconstituted as a liposomal aerosol for pulmonary delivery to improve the in vivo behavior of existing remdesivir cyclodextrin conclusion compound (Rdv-cyc) injections and liposome encapsulation endowed remdesivir with much higher solubility and better biocompatibility, and thus, increased the efficacy of the drug. The market is growing in the current scenario because the companies are still engaged in the development of therapeutics against COVID-19, in which liposome-based drugs or vaccines can play a vital role.

The major factor driving the growth of the liposome drug delivery market is the increasing demand for effective and efficient therapeutics since liposome-based drug delivery method offers certain advantages over other delivery systems. For instance, according to the research study published in Molecules Journal in February 2022, liposomes have better properties than standard drug delivery methods, such as site-targeting, prolonged or controlled release, drug protection from degradation and clearance, higher therapeutic effects, and lesser toxic side effects.

Also, the application of liposomes to assist drug delivery has shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving the biodistribution of compounds to target sites in vivo. This enables the effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes are an appealing delivery system due to their adaptable physicochemical and biophysical properties, which allow for easy manipulation to address various delivery concerns. Hence, they are the preferred choice of drug manufacturers.

Furthermore, with the increasing prevalence of chronic diseases such as cancer, diabetes, fungal infections, and others around the world, the demand for effective therapeutics is increasing, which is expected to fuel the growth of the liposome drug delivery market. For instance, according to the December 2021 update of the International Diabetes Federation (IDF), about 537 million adults of age 20 to 79 years were living with diabetes around the world in 2021, and this number is estimated to reach 643 million by 2030 and 783 million by 2045. The projected rise in the number of diabetes cases globally is expected to boost demand for liposomal diabetes therapeutics to increase its efficacy and reduce the toxicity and hence, drive growth of the studied market.

In addition, the increasing advancement in the liposomal drug delivery method with the new investments in the area along with product launches, acquisitions, and collaborations by the market players is further expected to boost the growth of the liposome drug delivery market. For instance, in October 2021, Evonik Health Care, an integrated contract development and manufacturing organization (CDMO) that offers excipients, formulation technologies, and clinical and commercial manufacturing, launched a new version of its established LIPEX liposome extruder. LIPEX Flow meets the market need for more efficient, next-generation high-pressure extruders to produce drug products requiring conventional liposomal drug delivery, including drugs for oncology, vaccines, and other applications.

Therefore, owing to the above-mentioned factors, the studied market is expected to experience significant growth during the study period. However, stringent regulatory policies and adverse effects associated with drug delivery are expected to restrain the growth of the liposome drug delivery market during the forecast period of the study.

Liposome Drug Delivery Industry Segmentation

As per the scope of the report, liposomes are lipid-based bilayer vesicles that can encapsulate, deliver, and release low-soluble drugs and small molecules to a specific target site in the body. They've been shown to help stabilize therapeutic compounds, overcome barriers to cellular and tissue uptake, and improve the biodistribution of compounds to target sites in vivo. Liposomes are a desirable delivery technology because of their adaptable physicochemical and biophysical features, which allow for easy customization to meet a variety of delivery needs. The liposome drug delivery market is segmented by product (liposomal paclitaxel, liposomal Doxorubicin, liposomal Amphotericin B, and others), technique (stealth liposome technology, non-PEGylated liposome technology, and DepoFoam liposome technology), indication (fungal infections/diseases, cancer therapeutics, pain management, viral vaccines, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.